T-cell Epitopes in Pf155/RESA, a Major Candidate for a Plasmodium Falciparum Malaria Vaccine
Overview
Affiliations
Immunogens included in a subunit vaccine should contain both B- and T-cell-activating sites to ensure anamnestic responses following reinfection after vaccination as well as antibody-independent cellular immunity. The Plasmodium falciparum antigen Pf155/RESA, a major candidate for a vaccine against the asexual blood stages of this malaria parasite, was investigated for T-cell epitopes in its C-terminal amino acid repeat region, a region known to be conserved in different P. falciparum strains. It was found to contain several related sequences that activated T cells from humans primed to P. falciparum by natural exposure, to proliferation, and/or interferon-gamma release in vitro. T cells from approximately half of the donor group investigated responded to the intact protein, and 65% of these responders also responded to short synthetic peptides, probably representing a small number of partly overlapping T-cell epitopes. Thus, sequences from the C terminus of Pf155 may be suitable constituents of a P. falciparum subunit vaccine and also provide a basis for epitope-specific epidemiological studies relating cellular immune responses in vitro to clinical immunity and P. falciparum endemicity.
Dasgupta G, Chentoufi A, Kalantari M, Falatoonzadeh P, Chun S, Lim C J Virol. 2012; 86(8):4358-69.
PMID: 22318137 PMC: 3318627. DOI: 10.1128/JVI.07107-11.
Guilbride D, Gawlinski P, Guilbride P PLoS One. 2010; 5(5):e10685.
PMID: 20502667 PMC: 2873430. DOI: 10.1371/journal.pone.0010685.
BenMohamed L, Thomas A, Druilhe P Infect Immun. 2004; 72(8):4376-84.
PMID: 15271893 PMC: 470687. DOI: 10.1128/IAI.72.8.4376-4384.2004.
Siddique A, Ahlborg N, Warsame M, Perlmann P, Berzins K Clin Exp Immunol. 1999; 116(3):493-9.
PMID: 10361240 PMC: 1905299. DOI: 10.1046/j.1365-2249.1999.00911.x.
Fagerberg J, Frodin J, Wigzell H, Mellstedt H Cancer Immunol Immunother. 1993; 37(4):264-70.
PMID: 8348565 PMC: 11038291. DOI: 10.1007/BF01518521.